REG - Cambridge Cognition - Cambridge Cognition and ActiGraph Partnership

Cambridge Cognition HoldingsAnnouncement

21/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240221:nRSU8300Da&default-theme=true

RNS Number : 8300D  Cambridge Cognition Holdings PLC  21 February 2024

 

21 February 2024

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Cambridge Cognition and ActiGraph Announce Partnership to Accelerate Adoption
of Digital Measurements for Central Nervous System Trials

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce a new
strategic partnership with ActiGraph, a leading provider of wearable
technologies for clinical trials. The partnership will deliver a broad suite
of assessments to provide a fully rounded view of mental and physical
capabilities. With both companies holding leading positions in their
respective markets, it is anticipated that the co-promotion planned under the
agreement will support growth in market share in the future.

 

ActiGraph's Accelerant(TM) partnership program is designed to advance the use
of digital health technologies (DHTs) in clinical development by simplifying
CROs' and technology vendors' access to raw data streams. As part of this
strategic partnership, Cambridge Cognition and ActiGraph will combine their
collective expertise in digital data collection to enhance assessment
capabilities in CNS trials in areas where there is a large unmet need, such as
schizophrenia and dementia.

 

Cambridge Cognition offers accurate and sensitive touch-screen and voice-based
digital assessments of cognition and other brain health indicators that have
been based on over 30 years of innovation and scientific validation.   The
Company's suite of e-clinical technology solutions can be used at home or
in-clinic, giving pharmaceutical companies and research institutions
flexibility to reliably capture a broad range of important clinical measures.
 

 

As well as being leaders in the collection of clinical insights for clinical
trials, both companies also lead in providing solutions for academic
researchers, enabling hundreds of research projects each year.  The
companies' technologies have been used together by top 20 pharmaceutical
companies in clinical trials already.  The combination of actigraphy data and
brain health assessments may enable more accurate multi-modal digital
biomarkers in the future.

 

 

Francesca Cormack, Chief Scientist, Cambridge Cognition, commented:

 

"CNS disorders are characterised by a host of heterogeneous symptoms which
impact daily life, but that are often inadequately addressed by existing
treatments. Our partnership with ActiGraph represents an exciting combination
of expertise in objective digital measures of actigraphy, speech and cognition
that will help accelerate the development of treatments for patients and
improve efficiency in clinical trials."

 

Christine Guo, Chief Scientific Officer, ActiGraph, commented:

 

"Digital health technologies give us the ability to collect data objectively
during a patient's everyday life. This is especially important in CNS
disorders where conventional assessments are prone to subjective biases. We
are excited about this partnership with Cambridge Cognition to provide
advanced clinical insights to study teams conducting CNS trials."

 

Enquiries:

 

 Cambridge Cognition Holdings plc                         Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer                   press@camcog.com (mailto:press@camcog.com)

 Stephen Symonds, Chief Financial Officer

 Panmure Gordon (UK) Limited (NOMAD and Joint Broker)     Tel: 020 7886 2968

 Freddy Crossley / Emma Earl                              (Corporate Finance)

 Rupert Dearden                                           (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                   Tel: 020 3903 7715

 David Poutney / James Serjeant

 Hudson Sandler (Financial PR and IR)                     Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus                           cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health, speech and language and
other specialist measurements in patients worldwide to improve clinical trial
outcomes, identify and stratify patients early and improve global efficiency
in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

About ActiGraph

 

ActiGraph is pioneering the digital transformation of clinical research. We
provide end-to-end digital health technology (DHT) solutions by integrating
and operationalizing the best hardware, software, and algorithms to generate
reliable evidence and get the right treatments to the right patients, faster.
ActiGraph's medical-grade wearable technology platform has been used to
capture real-world, continuous digital measures of activity, sleep, and
mobility for nearly 250 industry-sponsored clinical trials and thousands of
academic research studies. Appearing in over 23,000 published scientific
papers to date, ActiGraph is the most experienced and trusted wearable
technology partner in the industry.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRFLFITFRIIFIS